Nonsense Mutation & Premature Stop Codons (PTCs)
A nonsense mutation is a point mutation in a DNA sequence that converts a sense codon into one of three stop codons (UAA, UAG, or UGA), resulting in premature translation termination and a truncated protein.
Overview & Biological Context
Nonsense mutations are among the most deleterious point mutations in genetics. When a single base substitution transforms a normal codon (such as UGG [Trp] to UGA [Stop], or CAG [Gln] to UAG [Stop]), the ribosome terminates translation prematurely. The resulting truncated polypeptide is almost always dysfunctional and rapidly eliminated by the cell through nonsense-mediated mRNA decay (NMD) and targeted proteolysis.
Molecular Mechanism & Decoding
When the eukaryotic or prokaryotic ribosome reaches a newly created stop codon, no cognate aminoacyl-tRNA can bind. Instead, class-1 release factors (eRF1 in eukaryotes; RF1/RF2 in bacteria) recognize the stop triplet in the A-site, triggering peptidyl-tRNA hydrolysis and releasing the truncated nascent chain. In eukaryotes, if the premature stop codon is located more than 50-55 nucleotides upstream of an exon junction complex (EJC), it strongly recruits UPF1/UPF2/UPF3 to initiate Nonsense-Mediated Decay (NMD).
Full-Length Protein vs. Nonsense Truncation & mRNA Destruction
• Molecular defect: Translation halts at amino acid 41, producing a non-functional 41-aa peptide.
• NMD Surveillance: Exon Junction Complexes (EJCs) downstream recruit UPF1/UPF2 complexes, triggering rapid enzymatic degradation of the mRNA transcript.
Key Takeaways & Rules
The three universal stop codons are UAA (Ochre), UAG (Amber), and UGA (Opal).
Nonsense mutations near the N-terminus cause total loss of function; those in the extreme C-terminus may escape NMD.
Engineered tRNAs with mutated anticodons can suppress stop codons to incorporate non-canonical amino acids.
Clinical Significance & Laboratory Applications
Nonsense mutations account for approximately 11% of all described human gene lesions causing inherited diseases, including Duchenne Muscular Dystrophy (DMD), Cystic Fibrosis (CFTR G542X), and severe forms of Hemophilia. Groundbreaking translational therapies, including "readthrough" small molecules (ataluren/PTC124) and engineered suppressor tRNAs, aim to force the ribosome to insert an amino acid at premature stop codons to restore full-length functional proteins.
Related Online Analysis Tools
Frequently Asked Questions
What is the difference between a nonsense mutation and a missense mutation?
A missense mutation changes a codon from one amino acid to a different amino acid (e.g., GAG [Glu] to GTG [Val]), producing a full-length protein with a substituted residue. A nonsense mutation converts a codon to a STOP codon, cutting off translation and creating a truncated polypeptide.
Can nonsense mutations be treated with drugs?
Yes, translational readthrough therapy utilizes small molecules (such as ataluren, G418, or aminoglycosides) that bind the ribosome decoding center, allowing near-cognate tRNAs to insert an amino acid and continue translation through the premature stop codon.